There is disagreement in the medical community about a proposal to relabel prostate cancer Gleason score 6 (GS6) as non-cancerous, as detailed by recent commentaries in the Journal of Clinical ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

Stage 2 prostate adenocarcinoma is localized, with a nearly 100%, five-year relative survival rate. Diagnosis uses the TNM system, PSA levels and Gleason score to determine cancer stage and risk.